Britain and America have hammered out a major trade agreement that will guarantee no import taxes on UK medicine products entering the US market.
Key Provisions of the Accord
Under the terms of the agreement, the UK has agreed to boost funding on medicines through the National Health Service (NHS). This pledge secures that duties on these key products will remain at zero for a timeframe of the next three years.
This development is in response to earlier warnings to hike duties on patented pharmaceutical products, with increases discussed reaching one hundred percent.
"This deal with the UK bolsters the worldwide climate for new treatments and brings long-overdue balance to American-British medicine commerce," a release declared.
Trade Significance
Medicines constitute one of the the United Kingdom's most significant export categories to the US, which is by far the primary destination for major British pharmaceutical firms.
Export figures reveal that in the year leading up to September, the UK exported drugs valued at £11.1bn to the US. This figure represented nearly one-fifth of British export trade in that span.
"This deal secures work, boosts investment and facilitates the UK to establish itself as a global hub for biotech and pharma," the Business and Trade Secretary remarked.
Key UK Commitments
The deal includes several specific pledges from the British government:
- Price Threshold Increase: The UK will raise the affordability limit at which it deems new medicines to be unaffordable by twenty-five percent.
- Boosted Medicine Funding: There is a target to double overall public funding on medicines from 0.3 percent of GDP to 0.6% over the following ten-year period.
- Rebate Cap: The amount manufacturers must return to the NHS to prevent overspending will be restricted at 15%. Last year, refunds exceeded 20%.
Recent Tensions
The pact comes amid a long-running dispute between the pharmaceutical industry and the ministers over drug pricing and regulatory access.
The disagreement were intensified by arguments that American customers were paying significantly more for the same drugs than patients in the UK and Europe.
Over the last 18 months, several major pharmaceutical investments in the UK have been paused or scrapped, while major expansions have been pledged toward projects in the United States.
One official publicly accepted that the NHS needed to increase expenditure on drugs, noting that its spending on drugs had decreased as a percentage of its resources over the last ten years.
